qfx

The SEC filing hit Thursday, and it’s a signal. Triad now holds 3.87% of their reportable assets in this…enterprise. It’s not a tidal wave of cash, but it’s enough to raise an eyebrow – and maybe a glass of something strong. Compared to their holdings in Warner Bros. Discovery ($9.38 million), Google ($6.48 million), and other shiny objects, Macerich feels…different. Like a forgotten corner of the portfolio. A dark horse. Or maybe just a horse that’s about to be shot.

The filing with the Securities and Exchange Commission, dated as above, details the liquidation of 126,339 shares. The calculation of $17.83 million, derived from the average share price over the quarter, feels less like an objective valuation and more like an attempt to impose order on a fundamentally chaotic system. The fund’s position in QQEW now registers as zero, a stark and unsettling nullity. The net change, a precise $17.83 million, echoes with a bureaucratic finality that is, frankly, unnerving. One wonders about the internal procedures that led to this precise accounting, the endless forms and confirmations required to reach such a definitive conclusion.

One must, of course, acknowledge that the accumulation of capital through share repurchase is a perfectly respectable endeavor, and frequently a more advantageous one, from a tax perspective. Yet, for those of a more settled disposition – those who prefer a predictable return upon their investment – such maneuvers offer little comfort. For it is the steady, reliable income that allows for prudent planning and the maintenance of a comfortable independence.

The arrangement, while seemingly novel, echoes a pattern observed throughout history: the convergence of disparate disciplines to unlock concealed truths. Recall the medieval alchemists, who, through a blend of mysticism and observation, laid the groundwork for modern chemistry. This alliance, however, possesses a distinctly modern character, predicated not on empirical intuition, but on the relentless logic of computation. The laboratory, as described in the company pronouncements, will be powered by Nvidia’s Vera Rubin processors—a fitting name, considering Rubin’s own exploration of celestial patterns—acting as a digital oracle, divining potential therapeutics from the vastness of biological data.

The stock itself has experienced an upward trajectory exceeding 600% over the past year. One begins to suspect the numbers themselves are breeding, replicating with an unsettling disregard for underlying value. This week’s increase is, therefore, not an anomaly, but rather a continuation of a process whose ultimate destination remains frustratingly obscured.